NSRX
NSRX

Nasus Pharma Ltd

AMEX · Pharmaceuticals
$5.44
-0.36 (-6.21%)
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 16.90M 15.57M 15.33M
Net Income 2.99M 2.88M 3.11M
EPS
Profit Margin 17.7% 18.5% 20.3%
Rev Growth +19.1% +9.8% -6.9%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 8.79M 9.10M 10.20M
Total Equity 24.63M 26.89M 27.54M
D/E Ratio 0.36 0.34 0.37
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 3.97M 4.34M 3.61M
Free Cash Flow 3.54M 3.27M 3.55M